Anandamide dysfunction in prodromal and established psychosis
There is epidemiological evidence that frequent cannabis use in general and during puberty in particular increases the risk to suffer psychosis and psychotic symptoms. Based on these observations, there is growing interest in the role of the endogenous cannabinoid system (eCB system) - the point of...
Gespeichert in:
| 1. Verfasser: | |
|---|---|
| Dokumenttyp: | Article (Journal) |
| Sprache: | Englisch |
| Veröffentlicht: |
2012
|
| In: |
Current pharmaceutical design
Year: 2012, Jahrgang: 18, Heft: 32, Pages: 5188-5193 |
| ISSN: | 1873-4286 |
| DOI: | 10.2174/138161212802884843 |
| Online-Zugang: | Verlag, Volltext: http://dx.doi.org/10.2174/138161212802884843 Verlag, Volltext: http://www.eurekaselect.com/102853/article 
|
| Verfasserangaben: | F. Markus Leweke |
MARC
| LEADER | 00000caa a2200000 c 4500 | ||
|---|---|---|---|
| 001 | 1580740820 | ||
| 003 | DE-627 | ||
| 005 | 20220815002844.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 180906s2012 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.2174/138161212802884843 |2 doi | |
| 035 | |a (DE-627)1580740820 | ||
| 035 | |a (DE-576)510740820 | ||
| 035 | |a (DE-599)BSZ510740820 | ||
| 035 | |a (OCoLC)1341018064 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rda | ||
| 041 | |a eng | ||
| 084 | |a 33 |2 sdnb | ||
| 100 | 1 | |a Leweke, F. Markus |e VerfasserIn |0 (DE-588)1052094287 |0 (DE-627)787796859 |0 (DE-576)407845941 |4 aut | |
| 245 | 1 | 0 | |a Anandamide dysfunction in prodromal and established psychosis |c F. Markus Leweke |
| 264 | 1 | |c 2012 | |
| 300 | |a 6 | ||
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a Computermedien |b c |2 rdamedia | ||
| 338 | |a Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Gesehen am 06.09.2018 | ||
| 520 | |a There is epidemiological evidence that frequent cannabis use in general and during puberty in particular increases the risk to suffer psychosis and psychotic symptoms. Based on these observations, there is growing interest in the role of the endogenous cannabinoid system (eCB system) - the point of action for psychoactive cannabinoids - in psychiatric disorders and schizophrenia in particular. It has been hypothesized nearly two decades ago that the eCB system may play a pathophysiological role in schizophrenia either in terms of an endogenous malfunction of the system itself and/or of a secondary malfunction as a result of the use of exogenous cannabinoids like Δ 9-tetrahydrocannabinol, the major psychoactive phytocannabinoid in Cannabis sativa. To test this hypothesis, several studies have been performed investigating endogenous ligands to cannabinoid CB1-receptors such as anandamide both in cerebrospinal fluid and plasma of patients and controls. Here a mini-review of the role of anandamide in schizophrenia is provided. | ||
| 773 | 0 | 8 | |i Enthalten in |t Current pharmaceutical design |d Hilversum : Bentham Science Publ., 2000 |g 18(2012), 32, Seite 5188-5193 |h Online-Ressource |w (DE-627)325051666 |w (DE-600)2034245-7 |w (DE-576)273880217 |x 1873-4286 |7 nnas |a Anandamide dysfunction in prodromal and established psychosis |
| 773 | 1 | 8 | |g volume:18 |g year:2012 |g number:32 |g pages:5188-5193 |g extent:6 |a Anandamide dysfunction in prodromal and established psychosis |
| 856 | 4 | 0 | |u http://dx.doi.org/10.2174/138161212802884843 |x Verlag |x Resolving-System |3 Volltext |
| 856 | 4 | 0 | |u http://www.eurekaselect.com/102853/article |x Verlag |3 Volltext |
| 951 | |a AR | ||
| 992 | |a 20180906 | ||
| 993 | |a Article | ||
| 994 | |a 2012 | ||
| 998 | |g 1052094287 |a Leweke, F. Markus |m 1052094287:Leweke, F. Markus |d 60000 |e 60000PL1052094287 |k 0/60000/ |p 1 |x j |y j | ||
| 999 | |a KXP-PPN1580740820 |e 3024836918 | ||
| BIB | |a Y | ||
| SER | |a journal | ||
| JSO | |a {"physDesc":[{"extent":"6 S."}],"relHost":[{"physDesc":[{"extent":"Online-Ressource"}],"origin":[{"dateIssuedDisp":"2000-","publisher":"Bentham Science Publ.","publisherPlace":"Hilversum","dateIssuedKey":"2000"}],"note":["Gesehen am 15.04.24"],"id":{"zdb":["2034245-7"],"eki":["325051666"],"issn":["1873-4286"]},"pubHistory":["Nachgewiesen 6.2000 -"],"recId":"325051666","part":{"issue":"32","pages":"5188-5193","text":"18(2012), 32, Seite 5188-5193","extent":"6","volume":"18","year":"2012"},"title":[{"title":"Current pharmaceutical design","title_sort":"Current pharmaceutical design","subtitle":"dispatches from the front line of drug design"}],"disp":"Anandamide dysfunction in prodromal and established psychosisCurrent pharmaceutical design","language":["eng"],"type":{"media":"Online-Ressource","bibl":"periodical"}}],"person":[{"display":"Leweke, F. Markus","role":"aut","given":"F. Markus","family":"Leweke"}],"title":[{"title":"Anandamide dysfunction in prodromal and established psychosis","title_sort":"Anandamide dysfunction in prodromal and established psychosis"}],"origin":[{"dateIssuedKey":"2012","dateIssuedDisp":"2012"}],"note":["Gesehen am 06.09.2018"],"id":{"eki":["1580740820"],"doi":["10.2174/138161212802884843"]},"recId":"1580740820","name":{"displayForm":["F. Markus Leweke"]},"language":["eng"],"type":{"bibl":"article-journal","media":"Online-Ressource"}} | ||
| SRT | |a LEWEKEFMARANANDAMIDE2012 | ||